European Commission Approves Clovis’ Rubraca for Recurrent Ovarian Cancer

European Commission Approves Clovis’ Rubraca for Recurrent Ovarian Cancer
The European Commission recently authorized Rubraca (rucaparib) for the treatment for women with recurrent BRCA-mutant ovarian cancer with relapsed or progressive disease. The recent approval is for the maintenance treatment of recurrent epithelial, ovarian, fallopian tube or primary peritoneal cancer in women who are in a complete or partial response to platinum-based chemotherapy. "Rucaparib provides a unique opportunity within Europe for women with BRCA mutated ovarian cancer, for whom platinum chemotherapy isn’t an option, to receive an oral non-chemotherapy treatment,” Rebecca Kristeleit, PhD, lecturer and consultant of medical oncology at University College London, said in a press release. “In this group of patients with limited treatment options, rucaparib provides a much-needed oral targeted therapy for these women.” Rubraca is the first PARP inhibitor licensed for the treatment of ovarian cancer in the European Union. PARP inhibitors are a group of therapies that halt the activity of enzymes called poly ADP ribose polymerase, or PARP. PARP proteins play a key role in the life of a cell. When a strand of DNA is broken or damaged, PARPs act as a repair crew to help fix the damaged site, allowing the cell to live. For healthy cells, this is good, but in cancer cells where DNA repair is already co
Subscribe or to access all post and page content.